SCHEMBL1660912

SCHEMBL1660912

CC(C)(C)[Si](C)(C)Oc1cccc2c1CCC2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
HTR1A P08908 1/20 0.43
ADRB3 P13945 1/20 0.43
TSHR P16473 1/20 0.43
SLC6A4 P31645 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
ABCB1 P08183 2/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
S1PR1 P21453 1/20 0.38
BRAF P15056 1/20 0.38
CYP19A1 P11511 1/20 0.36
PDE4D Q08499 1/20 0.36
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
S100A4 P26447 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29993176 1.00 ADRB2 (0.43) ADRB2ADRB1HTR1AADRB3TSHR
SCHEMBL2487204 0.91 ADRB2 (0.52) ADRB2ADRB1HTR1AADRB3TSHR
SCHEMBL29588862 0.91 ADRB2 (0.52) ADRB2ADRB1HTR1AADRB3TSHR
SCHEMBL5153891 0.80 ADRB2 (0.37) ADRB2ADRB1HTR1AADRB3TSHR
SCHEMBL16593838 0.76 PTK2 (0.39) ABCB1PREP
SCHEMBL430401 0.75 ADRB2 (0.53) ADRB2ADRB1HTR1A
SCHEMBL165220 0.75 KDM4E (0.61) ALDH1A1GAAABCB1KDM4EHPGD
SCHEMBL29506042 0.75 KDM4E (0.61) ALDH1A1GAAABCB1KDM4EHPGD
SCHEMBL7096400 0.73 HPGD (0.38) ADRB2ADRB1HTR1AADRB3TSHR
SCHEMBL7096401 0.73 HPGD (0.38) ADRB2ADRB1HTR1AADRB3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 US disclosed
CN-117642392-A Preparation and application of compounds with immunoregulation function 上海轶诺药业有限公司 2024-03-01 CN disclosed
EP-3619206-B1 PYRIMIDINYLOXY BENZO-FUSED COMPOUNDS AS HERBICIDES FMC CORP (US) 2024-02-14 EP disclosed
WO-2022253327-A1 PREPARATION AND USE OF COMPOUND HAVING IMMUNOMODULATORY FUNCTION 上海轶诺药业有限公司 2022-12-08 WO disclosed
CN-115433210-A Preparation and application of compound with immunoregulation function 上海轶诺药业有限公司 2022-12-06 CN disclosed
US-11427549-B2 Pyrimidinyloxy benzo-fused compounds as herbicides FMC CORPORATION (US) 2022-08-30 US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 EP disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 EP disclosed
EP-3612525-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2021-10-27 EP disclosed
EP-3612525-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2021-10-27 EP disclosed
US-7074863-B2 Metallocene catalysts containing an idenyl moiety substituted at the 4,-5,-6- or 7-position by a siloxy or germyloxy group BOREALIS TECHNOLOGY OY (FI) 2006-07-11 US disclosed
US-20040152882-A1 Metallocene catalysts containing an idenyl moiety substituted at the 4,-5,-6- or 7-position by a siloxy or germyloxy group BOREALIS TECHNOLOGY OY (FI) 2004-08-05 US disclosed
EP-1401880-A1 METALLOCENE CATALYSTS CONTAINING AN INDENYL MOIETY SUBSTITUTED AT THE 4-, 5-, 6- OR 7-POSITION BY A SILOXY OR GERMYLOXY GROUP Borealis Technology Oy (FI) 2004-03-31 EP disclosed
WO-2003000744-A1 METALLOCENE CATALYSTS CONTAINING AN IDENYL MOIETY SUBSTITUTED AT THE 4-, 5-, 6- OR 7-POSITION BY A SILOXY OR GERMYLOXY GROUP BOREALIS TECHNOLOGY OY (FI) 2003-01-03 WO disclosed
EP-0288962-B1 Aryl-aralkyl ethers, processes for their preparation and pharmaceutical composition comprising them FUJISAWA PHARMACEUTICAL CO (JP) 1994-07-13 EP disclosed
US-5061718-A BENZOTHIAZOLYLMETHOXY COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS ANTI-INFLAMMATORY OR ANTI-ALLERGENIC AGENTS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-10-29 US disclosed
US-5045548-A Lipoxygenase inhibitors FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-09-03 US disclosed
US-4965274-A Antiallergen, antiinflammatory agent; lipoxygenase FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-10-23 US disclosed
US-4923881-A ANTIINFLAMMATORY AGENTS, ANTIALLERGENS Fujisawa Phatmaceutical Co., Ltd. (JP) 1990-05-08 US disclosed
EP-0288962-A2 Aryl-aralkyl ethers, processes for their preparation and pharmaceutical composition comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427549-B2 Pyrimidinyloxy benzo-fused compounds as herbicides DDT, CNPY2, CBR3 ADRB2 1961/4885ADRB1 2016/4885HTR1A 3758/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 ADRB2 195/4885ADRB1 76/4885HTR1A 1813/4885
US-20040152882-A1 Metallocene catalysts containing an idenyl moiety substituted at the 4,-5,-6- or 7-position by a siloxy or germyloxy group IPO4, GEMIN4, GEMIN5 ADRB2 4335/4885ADRB1 4713/4885HTR1A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.